新型列线图用于判定转移性去势抵抗性前列腺癌患者能否从镭-223二氯化物治疗中获得最大获益:日本前列腺癌骨扫描指数镭-223治疗(J-RAP-BSI)试验
该回顾性多中心研究纳入258例接受镭-223治疗的转移性去势抵抗性前列腺癌患者,基于7项预后因素构建列线图预测总生存。列线图区分度良好,表观和乐观校正Harrell一致性指数分别为0.748和0.734,在符合欧洲药品管理局(EMA)建议的227例患者中分别为0.722和0.704。作者认为该列线图有助于治疗决策,无论是否符合EMA建议。
要点
- 列线图纳入既往治疗史评分、ECOG体能状态、PSADT、血红蛋白、LDH、ALP和aBSI共7项因素。
- 全队列列线图表观和乐观校正Harrell一致性指数分别为0.748和0.734。
- 符合EMA建议的227例患者中,表观和乐观校正Harrell一致性指数分别为0.722和0.704。
核心结论
- 作者认为,纳入aBSI的新型列线图可用于筛选可能从镭-223治疗中获得显著延长总生存的mCRPC患者,有助于治疗决策,无论是否符合EMA建议。
研究设计与样本
- 日本J-RAP-BSI试验为回顾性多中心研究,纳入2016年6月至2020年8月期间在日本接受镭-223治疗的258例mCRPC患者,具备治疗前骨显像、临床数据和生存结局。
- 采用基于最小绝对收缩和选择算子Cox回归模型的预后因素构建列线图,并对符合EMA指南的患者进行亚组分析。
主要发现
- 首次镭-223治疗后中位17.4个月内,124例(48.1%)死于前列腺癌。
- 预测因素包括既往治疗史评分(评分0:从未接受新型雄激素受体靶向药物(ARTA)治疗、从未接受紫杉烷类化疗、曾接受双膦酸盐/地舒单抗治疗)、ECOG体能状态、PSADT、血红蛋白、LDH、ALP水平和基于骨显像的aBSI值。
- 全队列列线图表观和乐观校正Harrell一致性指数分别为0.748和0.734;1、2、3年时间依赖AUC分别为0.771、0.818和0.771。
- 符合EMA建议的227例患者中,列线图表观和乐观校正Harrell一致性指数分别为0.722和0.704;1、2、3年时间依赖AUC分别为0.747、0.790和0.759。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop a novel nomogram for determining radium-223 dichloride (Ra-223) treatment suitability for metastatic castration-resistant prostate cancer (mCRPC) patients. METHODS: This Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial was a retrospective multicenter investigation enrolled 258 mCRPC patients in Japan with Ra-223 treatment between June 2016 and August 2020, with bone scintigraphy findings before treatment, clinical data, and survival outcome available. A nomogram was constructed using prognostic factors for overall survival (OS) based on a least absolute shrinkage and selection operator Cox regression model. A sub-analysis was also conducted for patients meeting European Medicines Agency (EMA) guidelines. RESULTS: Within a median of 17.4 months after initial Ra-223 treatment, 124 patients (48.1%) died from prostate cancer. Predictive factors included (1) sum of prior treatment history (score 0, never prior novel androgen receptor-targeted agents (ARTA) therapy, never prior taxane-based chemotherapy, and ever prior bisphosphonate/denosumab treatment), (2) Eastern Cooperative Oncology Group (ECOG) performance status, (3) prostate-specific antigen doubling time (PSADT), (4) hemoglobin, (5) lactate dehydrogenase (LDH), and (6) alkaline phosphatase (ALP) levels, and (7) automated bone scan index (aBSI) value based on bone scintigraphy. The nomogram using those factors showed good discrimination, with apparent and optimism-corrected Harrell's concordance index values of 0.748 and 0.734, respectively. Time-dependent area under the curve values at 1, 2, and 3 years were 0.771, 0.818, and 0.771, respectively. In 227 patients meeting EMA recommendation, the nomogram with seven factors showed good discrimination, with apparent and optimism-corrected Harrell's concordance index values of 0.722 and 0.704, respectively. Time-dependent area under the curve values at 1, 2, and 3 years were 0.747, 0.790, and 0.759, respectively. CONCLUSION: This novel nomogram including aBSI to select mCRPC patients to receive Ra-223 with significantly prolonged OS possibility was found suitable for assisting therapeutic decision-making, regardless of EMA recommendation.
引用
- Kitajima K, Igeta M, Kuyama J, et al. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial. Eur J Nucl Med Mol Imaging. 2022. PMID: 36539508. doi:10.1007/s00259-022-06082-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。